A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors
Phase 2
N/A
21 Years
N/A
21 Years
Not Enrolling
Both
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Recurrent Adrenocortical Carcinoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer
Both
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Recurrent Adrenocortical Carcinoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer
Trial Information
A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors
OBJECTIVES:
I. Determine the response rate in children with recurrent or refractory solid tumors treated
with oxaliplatin.
II. Determine the cumulative toxicity of this drug in these patients. III. Determine the
pharmacokinetic profile of this drug in these patients. IV. Determine time to progression
and overall survival of patients treated with this drug.
V. Correlate the extent of oxaliplatin exposure with response in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to disease type.
Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for
up to 17 courses in the absence of disease progression or unacceptable toxicity.
Inclusion Criteria:
- Histologically confirmed* solid tumor, including any of the following:
- Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET)
- Osteosarcoma
- Rhabdomyosarcoma
- Neuroblastoma
- High-grade astrocytoma
- Low-grade astrocytoma
- Glioblastoma multiforme
- Ependymoma
- Hepatoblastoma
- Germ cell tumors of any site
- Rare tumors of interest, including any of the following:
- Soft tissue sarcoma
- Hepatocellular carcinoma
- Childhood/adolescent colorectal carcinoma
- Childhood/adolescent renal cell carcinoma
- Childhood/adolescent adrenocortical carcinoma
- Childhood/adolescent nasopharyngeal carcinoma
- Recurrent disease OR refractory to conventional therapy
- Measurable disease by clinical exam, CT scan, MRI, or positron emission tomography
- Performance status - Karnofsky 50-100% (for patients over age 10)
- Performance status - Lansky 50-100% (for patients age 10 and under)
- At least 8 weeks
- Absolute neutrophil count ≥ 1,000/mm^3*
- Platelet count ≥ 75,000/mm^3* (transfusion independent)
- Hemoglobin ≥ 8.0 g/dL* (RBC transfusions allowed)
- Granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow metastases or
extensive prior radiotherapy allowed provided the above hematological criteria are
met
- Bilirubin ≤ 3 mg/dL
- Creatinine based on age as follows:
- ≤ .8 mg/dL (for patients age 5 and under)
- ≤ 1.0 mg/dL (for patients age 6 to 10)
- ≤ 1.2 mg/dL (for patients age 11 to 15)
- ≤1.5 mg/dL (for patients age 16 to 21)
- Creatinine clearance or radioisotope glomerular filtration rate > 20 mL/min
- No uncontrolled seizure disorder
- No uncontrolled infection
- CNS toxicity ≤ grade 2
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Recovered from prior immunotherapy
- At least 7 days since prior anticancer biologic therapy
- More than 1 week since prior growth factors
- At least 6 months since prior allogeneic stem cell transplantation
- No evidence of active graft-vs-host disease
- No concurrent immunomodulating agents
- Recovered from prior chemotherapy
- No prior oxaliplatin
- Prior carboplatin or cisplatin allowed
- More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for
nitrosoureas)
- No other concurrent anticancer chemotherapy
- Concurrent dexamethasone for CNS tumors allowed provided patient has been on a stable
or decreasing dose for ≥ 1 week before study entry
- Recovered from prior radiotherapy
- At least 2 weeks since prior local palliative radiotherapy (small port)
- At least 6 months since prior craniospinal radiotherapy
- At least 6 months since prior radiotherapy to ≥ 50% of the pelvis
- At least 6 weeks since other prior substantial radiotherapy to the bone marrow
- Concurrent radiotherapy to localized painful lesions allowed provided ≥ 1 measurable
lesion is not irradiated
- No other concurrent investigational agents
- No other concurrent anticancer agents
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Response rate
Outcome Description:
Response rate and confidence intervals will be constructed according to the method of Chang and O'Brien.
Outcome Time Frame:
Up to 3 years
Safety Issue:
No
Principal Investigator
Orren Beaty
Investigator Role:
Principal Investigator
Investigator Affiliation:
Children's Oncology Group
Authority:
United States: Food and Drug Administration
Study ID:
NCI-2012-01815
NCT ID:
NCT00091182
Start Date:
October 2004
Completion Date:
Related Keywords:
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Extragonadal Germ Cell Tumor
- Childhood Hepatoblastoma
- Childhood Hepatocellular Carcinoma
- Childhood High-grade Cerebral Astrocytoma
- Childhood Low-grade Cerebral Astrocytoma
- Childhood Malignant Ovarian Germ Cell Tumor
- Childhood Malignant Testicular Germ Cell Tumor
- Childhood Teratoma
- Recurrent Adrenocortical Carcinoma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Ependymoma
- Recurrent Childhood Liver Cancer
- Recurrent Childhood Malignant Germ Cell Tumor
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Recurrent Colon Cancer
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Nasopharyngeal Cancer
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma
- Recurrent Rectal Cancer
- Recurrent Renal Cell Cancer
- Astrocytoma
- Carcinoma
- Colonic Neoplasms
- Rectal Neoplasms
- Carcinoma, Renal Cell
- Ependymoma
- Glioma
- Liver Neoplasms
- Neuroblastoma
- Osteosarcoma
- Rhabdomyosarcoma
- Teratoma
- Testicular Neoplasms
- Nasopharyngeal Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Hepatoblastoma
- Adrenocortical Carcinoma
- Rhabdomyosarcoma, Embryonal
- Sarcoma
- Germinoma
- Ovarian Neoplasms
- Optic Nerve Glioma
- Sarcoma, Ewing's
- Neuroectodermal Tumors, Primitive, Peripheral
- Carcinoma, Hepatocellular
Name | Location |
|---|---|
| Children's Oncology Group | Arcadia, California 91006-3776 |
